 Updates in Heart Failure:From Definition to Treatments and Everything In-Between | |
| 主辦單位 | 社團法人高雄縣醫師公會 |
| 協辦單位 | 高雄市立鳳山醫院（委託財團法人長庚紀念醫院經營） |
| 上課日期時間 | 111年3月8日（星期二）12:30~14:30為因應COVID-19疫情二級警戒之室內不得超過八十人之規定，參加實體課程敬請事先報名 |
| 課程地點 | 實體課程：高雄市立鳳山醫院（委託財團法人長庚紀念醫院經營）八樓會議室（高雄市鳳山區經武路42號） 會議網址： https://cgmh.webex.com/cgmh/j.php?MTID=mfbc34918392ae3d2586002eda1cbf94c 會議室ID：25113998119 會議密碼：od04yAfY |
| 實體課程報名截止日期 | 2022/03/01 PM 16:59或額滿(80)為止 視訊課程免報名 |
| 講師 | 方志元／長庚醫療財團法人高雄長庚紀念醫院心臟血管內科 |
| 課程大綱 | THE PREVALENCE AND BURDEN OF HEART FAILURE (HF) IN THE UNITED STATES ARE PREDICTED TO INCREASE An estimated 6.5 million Americans have HF, and 1 million new HF cases occur annually. The number of Americans living with HF will increase 46% by 2030, due to an aging population and advances in HF therapies. Half of those diagnosed with HF will die within 5 years. WHERE IS THE GUIDELINE-DIRECTED MEDICAL THERAPY (GDMT) FOR HF? Of 3518 patients with HF with reduced ejection fraction (HFrEF) • Fewer than 25% received all 3 GDMT classes (ie, ACE/ARB/ARNI, BB], MRA) • When prescribed, fewer than half of patients received target doses of ACE/ARB/ARNI and BB • Only 1% received target doses of all 3 GDMT classes 2021 UPDATE TO AMERICAN COLLEGE OF CARDIOLOGY (ACC) EXPERT CONSENSUS PATHWAY FOR HF WITH FOCUS ON HOW (NOT WHY) TO DEPLOY TREATMENTS The ACC Consensus recommendations are in step with the European Society of Cardiology HF guidelines, which recommend: • Quadruple therapy with ARNI, BB, MRA, and SGLT2 inhibitor as the foundational cornerstone of HF therapy • Initiation of low doses of all 4 drug classes, and then subsequent titration of the renin-angiotensin system inhibitor and BB doses. (The ACC/AHA/HFSA HF guidelines are in development.) SGLT2 INHIBITORS: THE NEW KIDS ON THE HF BLOCK DAPA-HF Trial (N = 4744; 42% with diabetes): Dapagliflozin reduced the risk for worsening HF or cardiovascular death by 26% vs placebo (HR: 0.74; 95% CI: 0.65, 0.85; P < .001) in patients with HFrEF (EF ≤ 40%) regardless of the presence or absence of diabetes. EMPEROR-Reduced Trial (N = 3730; 50% with diabetes): Empagliflozin reduced the risk for worsening HF or cardiovascular death by 25% vs placebo (HR: 0.75; 95% CI: 0.65, 0.86; P < .001) in patients with HFrEF regardless of the presence or absence of diabetes. EMPEROR-Preserved Trial (N = 5988; 49% with diabetes): Among patients with HF with preserved EF (HFpEF; EF > 40%), empagliflozin reduced the risk for worsening HF or cardiovascular death by 21% vs placebo (HR: 0.79; 95% CI: 0.69, 0.90; P < .001). |
| 積分 | 西醫師繼續教育積分-專業課程、家醫科（僅限實體課程）、內科（僅限實體課程） |